Key Points
-
Adverse drug effects are an important cause of morbidity and mortality, which account for up to 5% of all hospital admissions. Immune-mediated adverse drug effects (IMADEs), although they are uncommon with some drug classes (for example, β-lactam-containing penicillin and cephalosporin derivatives), can occur in up to 10% of patients who are at risk.
-
IMADEs can affect many tissues and organs, including the skin, lungs, liver and kidneys. Although they are usually mild (for example, minor rashes), IMADEs can be severe and can lead to organ failure or life-threatening anaphylaxis.
-
Although the precise links are undefined, it is clear that genetic factors are important risk factors for IMADEs. Genetic polymorphisms have been identified in several biological systems that contribute to IMADEs, including drug-metabolizing enzymes, major histocompatibility complex antigens and immune receptors.
-
Important advances are beginning to be made in our understanding of the role of genetic polymorphisms as risk factors. The association between mutations in the gene for arylamine N-acetyltransferase and hypersensitivity to sulphonamides, sulphasalazine and dapsone, and between expression of the HLA-B*5701 phenotype and hypersensitivity to abacavir in HIV patients, are examples of areas in which these advances are beginning to bear fruit.
-
Because of their rarity, the study of the genetics of IMADEs is difficult. Moreover, owing to the inherent differences among species, models that are conducted in wild-type rodents have limited predictive value for humans.
-
It is anticipated that the growing catalogue of polymorphisms, coupled with advances in in silico modelling and the availability of increasingly sophisticated transgenic-rodent test systems, will improve the diagnosis and prediction of IMADEs, and, ultimately, the discovery and development of drugs with a markedly decreased risk of causing them.
Abstract
Adverse drug effects (ADEs) are of great importance in medicine and account for up to 5% of all hospital admissions. ADEs can arise from several mechanisms and a wide range of drugs can cause immune-mediated ADEs (IMADEs). For a drug to elicit an IMADE, it must be both immunogenic (that is, able to sensitize the immune system) and antigenic (that is, able to evoke a response from a sensitized immune system). Unlike protein therapeutics, small-molecule drugs (or xenobiotics) are usually neither immunogenic nor antigenic. IMADEs are therefore the result of complex interactions between drug-metabolizing enzymes, immune sensitization and immune effectors. The genetic aspects of this interplay are discussed in this review.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Johnson-Reagan, L. & Bahna, S. L. Severe drug rashes in three siblings simultaneously. Allergy 58, 445–447 (2003).
Chaplin, D. D. Overview of the immune response J. Allergy Clin. Immunol. 111, S442–S449 (2003).
Naisbitt, D. J., Gordon, S. F., Pirmohamed, M. & Park, B. K. Immunological principles of drug reactions. The initiation and propagation of immune responses elicited by drug treatment. Drug Safety 23, 483–507 (2000). This is an important review of immune-mediated adverse drug effects.
Neugut, A. I., Ghatak, A. T. & Miller, R. L. Anaphylaxis in the United States and investigation into its epidemiology. Arch. Intern. Med. 161, 15–21 (2001). An interesting analysis of the incidence and causes of anaphylaxis, including drug-mediated cases.
Koren, E., Zuckerman, L. A. & Mire-Sluis, A. R. Immune responses to therapeutic proteins in humans: clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3, 349–360 (2002).
Bugelski, P. J. & Treacy, G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Therapeutics 6, 10–16 (2004).
Landsteiner, K. & Jacobs, J. Studies on the sensitization of animals with simple chemical compounds. J. Exp. Med. 61, 643–656 (1935).
Li, A. P. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chemico-Biol. Interact. 142, 7–23 (2002).
Bougie, D., Johnson, S. T., Weitekamp, L. A. & Aster, R. H. Sensitivity to a metabolite of diclonfenac as a cause of immune hemolytic anemia. Blood 90, 407–413 (1997).
Rieder, M. J., Shear, N. H., Kanee, A., Tang, B. K. & Spielberg, S. P. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin. Pharmacol. Ther. 49, 13–17 (1991).
Park, B. K., Pirmohamed, M. & Kitteringham, N. R. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br. J. Clin. Pharmacol. 34, 377–395 (1992).
Munthe, L. A., Os, A., Zangani, M. & Bogen, B. MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. J. Immunol. 172, 7476–7484 (2004).
Pichler, W. J. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139, 683–693 (2003).
Stevanoviae, S. Structural basis of immunogenicity. Transplant. Immunol. 10, 122–136 (2002). This report presents a clear discussion of HLA proteins.
Simeoni, L., Kliche, S., Lindquist, J. & Schraven, B. Adaptors and linkers in T and B cells. Curr. Opin. Immunol. 16, 304–313 (2004).
Wang, H. & Clarke, S. H. Regulation of B-cell development by antibody specificity. Curr. Opin. Immunol. 16, 246–250 (2004).
Cavani, A., Ottaviani, C., Nasorri, F., Sebastiani, S. & Girolomoni, G. Immunoregulation of hapten and drug induced immune reactions. Curr. Opin. Allergy Clin. Immunol. 3, 243–247 (2003).
Pirmohamed, M., Naisbitt, D. J., Gordon, F. & Park, B. K. The danger hypothesis: potential role in idiosyncratic drug reactions. Toxicology 181–182, 55–63 (2002). A thorough discussion of the implications of the danger hypothesis for IMADEs.
Layton, G. T., Stanworth, D. R. & Amos, H. E. Factors influencing the immunogenicity of the haptenic drug chlorhexidine in mice. II. The role of the carrier and adjuvants in the induction of IgE and IgG anti-hapten responses. Immunology 59, 459–465 (1986).
Ohashi, P. S. & DeFranco, A. L. Making and breaking tolerance. Curr. Opin. Immunol. 14, 744–759 (2002).
Pichler, W. J. Drug-induced autoimmunity. Curr. Opin. Allergy Clin. Immunol. 3, 249–253 (2003). This paper raises the prospect that IMADEs and autoimmunity might be linked.
Coombs, R. R. A. & Gell, P. G. H. in Clinical Aspects of Immunology (eds Gell, P., Coombs, R. R. A. & Lacjman, P. J.) 761–781 (Blackwell Scientific Publications, Oxford, 1975).
Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. & Coffman, R. L. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348–2357 (1986). An introduction to the concept of the polarization of T H cell function into T H 1 cells that drive delayed (cell-mediated) immune responses, and T H 2 cells that drive immediate (allergic or IgE-mediated) immune responses.
Gaspard, I. et al. IL-4 and interferon-γ mRNA induction in human peripheral lymphocytes specific for β-lactam antibiotics in immediate or delayed hypersensitivity reactions. J. Clin. Immunol. 20, 107–116 (2000).
Zanni, M. P. et al. T cell reactions in patients showing adverse immune reactions to drugs. Inflamm. Res. 45 (Suppl. 2), S79–S84 (1996).
DeShazo, R. & Kemp, S. Allergic reactions to drugs and biologic agents. J. Am. Med. Assoc. 278, 1895–1906 (1997).
Gruchalla, R. S. Understanding drug allergies. J. Allergy Clin. Immunol. 105, S637–S644 (2000).
Andrès, E. et al. Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients. Drugs Aging 21, 427–435 (2004).
Podevin, P. & Biour, M. Drug induced “allergic hepatitis”. Clin. Rev. Allergy Immunol. 13, 223–244 (1995).
Ravnskov, U. Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of a common mechanism. Br. J. Clin. Pharmacol. 47, 203–210 (1999).
Ingelman-Sundberg, M. Functional consequences of xenobiotic metabolizing enzymes. Toxicol. Lett. 102–103, 155–160 (1998).
Johansson, I. et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA 90, 11825–11829 (1993).
Heim, M. H. & Meyer, U. A. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336, 529–532 (1990).
Pirmohamed, M. et al. Association analysis of drug-metabolizing enzyme gene polymorphisms in HIV patients with co-trimoxazole hypersensitivity. Pharmacogenetics 10, 705–713 (2000).
Furet, Y. et al. Pertinence clinique du polymorphisme génétique de la N-acétyltransférase de type 2 (NAT2). Therapie 57, 427–431 (2002).
Alfirevic, A. et al. Slow acetylator phenotype and genotype in HIV-positive patients with sulfamethoxazole hypersensitivity. Br. J. Clin. Pharmacol. 55, 158–165 (2003).
O'Neil, W. M. et al. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J. Clin. Pharmacol. 42, 613–619 (2002).
Green, V. J. et al. Genetic analysis of microsomal epoxide hydrolases in patients with carbamazepine hypersensitivity. Biochem. Pharmacol. 50, 1353–1359 (1995).
Gaedigk, A., Spielbereg, S. P. & Grant, D. M. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 4, 142–153 (1994).
Burchell, B. Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation. Am. J. Pharmacogenomics 3, 37–52 (2003).
King, C. D., Rios, G. R., Green, M. D. & Tephly, T. R. UDP-glucuronosyltransferases. Curr. Drug Metab. 1, 143–161 (2000).
McFadden, S. A. Phenotypic variations in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. Toxicology 111, 43–65 (1996).
Ates, N. A. et al. Glutathione S-transferase polymorphisms in patients with drug eruption. Arch. Dermatol. Res. 295, 429–433 (2004).
Westphal, G. A. et al. Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization. Int. Arch. Occup. Environ. Health 73, 384–388 (2000).
Tiercy, J. M. Molecular basis of HLA polymorphism: implications in clinical transplantation. Transplant. Immunol. 9, 173–180 (2002).
Apanius, V., Penn, D., Slev, P. R., Ruff, L. R. & Potts, W. K. The nature of selection on the major histocompatibility complex. Crit. Rev. Immunol. 17, 179–224 (1997).
Selvakumar, A., Steffens, U. & Dupont, B. Polymorphism and domain variability of human killer cell inhibitory receptors. Immunol. Rev. 155, 183–196 (1997).
Daser, A., Mitchison, H., Mitchison, A. & Muller, B. Non-classical-MHC genetics of immunological diseases in man and mouse. The key role of pro-inflammatory cytokine genes. Cytokine 8, 593–597 (1996).
Császár, A. & Ábel, T. Receptor polymorphisms and disease. Eur. J. Pharmacol. 414, 9–22 (2001).
Zhou, P., Cao, H., Smart, M. & David, C. Molecular basis of genetic polymorphism in major histocompatibility complex-linked proteasome gene (Lmp-2). Proc. Natl Acad. Sci. USA 90, 2681–2684 (1993).
Vandebriel, R. J. Gene polymorphism within the immune system that may underlie drug allergy. Naunyn-Schmiedeberg Arch. Pharmacol. 369, 125–132 (2004). This paper takes a pragmatic approach to the issue of polymorphisms.
Newton, J. L. et al. Dissection of class III major histocompatibility complex haplotypes associated with rheumatoid arthritis. Arthritis Rheum. 50, 2122–2129 (2004).
Spengler, H. & de Weck, A. L. Evaluation of genetic control of the immune response to penicillin in man. Monogr. Allergy 11, 116–123 (1977).
Panayi, G. S., Wooley, P. & Batchelor, J. R. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations and toxic reactions to drugs. Br. Med. J. 2, 1326–1328 (1978).
Ju, L. Y. et al. A possible linkage of HLA-DRB haplotypes with tiopronin intolerance in rheumatoid arthritis. Clin. Exp. Rheumatol. 12, 249–254 (1994).
Kalyoncu, A. F. et al. Analgesic intolerance with or without bronchial asthma: is there a marker? J. Investig. Allergol. Clin. Immunol. 13, 162–169 (2003).
Molnar-Gabor, E., Endreffy, E. & Rozasi, A. HLA-DRB1, DQA1 and DQB1 genotypes in patients with nasal polyposis. Laryngoscope 110, 422–425 (2000).
Mullarkey, M. F., Thomas, P. S., Hansen, J. A., Webb, D. R. & Nisperos, B. Association of aspirin-sensitive asthma with HLA-DQw2. Am. Rev. Respir. Dis. 133, 261–263 (1986).
Mastalerz, L., Setkowicz, M., Sanak, M. & Szczeklik, A. Hypersensitivity to aspirin: common ecosanoid alterations in urticaria and asthma. J. Allergy Clin. Immunol. 113, 771–775 (2004).
Kedda, M. A. et al. Characterization of two polymorphisms in the leukotriene C4 synthase gene in an Australian population of subjects with mild, moderate and severe asthma. J. Allergy Clin. Immunol. 113, 889–895 (2004).
Kowalski, M. L., Woszczek, G., Bienkiewicz, B. & Mis, M. Association of pyrazolone drug hypersensitivity with HLA-DQ and DR antigens. Clin. Exp. Allergy 28, 1153–1158 (1998).
Quiralte, J. et al. Association of HLA-DR11 with anaphylactoid reactions caused by nonsteroidal anti-inflammatory drugs. J. Allergy Clin. Immunol. 103, 685–989 (1999).
Romano, A. et al. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann. Allergy Asthma Immunol. 80, 433–437 (1998).
Russek, G. I. et al. Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype. Quart. J. Med. 65, 845–852 (1987).
Chung, W. H. et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 428, 486 (2004).
Mallal, S. et al. Association between presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727–732 (2002).
Hetherington, S. et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121–1122 (2002).
Martin, A. M. et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101, 4180–4185 (2004). Along with reference 66, this paper shows a strong correlation between HLA phenotype and the risk of hypersensitivity for abacvir.
Center for Drug Evaluation and Research, Food and Drug Administration. Guidance for Industry. General Considerations for the Clinical Evaluation of Drugs. HEW Publication No. (FDA) 77-3040 (1997).
Lebovitz, H. E., Kreider, M., Freed, M. I. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25, 815–821 (2002).
Pichler, W. J. & Tilch, J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 59, 809–820 (2004).
Gaspard, I., Kerdine, S., Pallardy, M. & Lebrec, H. Quantitation of cytokine mRNA expression as an endpoint for prediction and diagnosis of xenobiotic-induced hypersensitivity reactions. Methods 19, 64–70 (1999).
Becquemont, L. Clinical relevance of pharmacogenetics. Drug Metab. Rev. 35, 277–285 (2003).
Roses, A. D. Pharmacogenetics and the practice of medicine. Nature 405, 857–865 (2000).
ICH Topic E9: Statistical Principles for Clinical Trials (European Agency for the Evaluation of Medical Products, London, 1989).
Park, B. K. & Pirmohamed, M. Toxicogenetics in drug development. Toxicol. Lett. 120, 281–291 (2001).
Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A. & Stevanovic, S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213–219 (1999).
Linder, M. W., Prough, R. A. & Valdes, R. Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem. 43, 254–266 (1997).
Board, P., Blackburn, A., Jermiin, L. S. & Chelvanayagam, G. Polymorphism of phase II enzymes: identification of new enzymes and polymorphic variants by database analysis. Toxicol. Lett. 102–103, 149–154 (1998).
Alhenc-Gelas, F. et al. Pharmacogénétique, étude du génome et développement des médicaments. Therapie 58, 275–282 (2003).
Choquet-Kastylevsky, G. & Descotes, J. Value of animal models for predicting hypersensitivity reactions to medicinal products. Toxicology 129, 27–35 (1998).
Weaver, J. L. et al. Detection of systemic hypersensitivity to drugs using standard guinea pig assays. Toxicology 193, 203–217 (2003).
Nierkens, S., Nieuwenhuijsen, L., Thomas, M. & Pieters, R. Evaluation of the use of reported antigens in an auricular lymph node assay to asses the immunosensitizing potential of drugs. Toxicol. Sci. 79, 90–97 (2004).
Warbrick, E. V., Dearman, R. J. & Kimber, I. Prediction of drug allergenicity: possible use of the local lymph node assay. Curr. Opin. Drug Discov. Dev. 4, 60–65 (2001).
Ravel, G., Christ, M., Horand, F. & Descotes, J. Cytokine release does not improve the sensitivity and specificity of the direct popliteal lymph node assay. Toxicology 200, 247–254 (2004).
Dean, J. H. et al. ICCVAN evaluation of the murine local lymph node assay. Conclusions and recommendations of an independent scientific peer review panel. Regul. Toxicol. Pharmacol. 34, 258–273 (2001).
Masson, M. J. & Uetrecht, J. P. Tolerance induced by low dose d-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated. Chem. Res. Toxicol. 17, 82–94 (2004).
Shenton, J. M., Teranishi, M., Abu-Asab, M. S., Yager, J. A. & Uetrecht, J. P. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem. Res. Toxicol. 16, 1078–1089 (2003).
Mestas, J. & Hughes, C. C. W. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731–2738 (2004).
Taneja, V. & David, C. S. HLA transgenic mice as humanized mouse models of disease and immunity. J. Clin. Invest. 101, 921–926 (1998).
Nabozy, G. H. et al. HLA-DQ8 transgenic mice are highly susceptible to collagen induced arthritis. A novel model of human polyarthritis. J. Exp. Med. 183, 27–37 (1996).
Kong, Y. M. et al. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J. Exp. Med. 184, 1167–1172 (1996).
Wicker, L. S. et al. Naturally process T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for type I diabetes-associated MHC class II allele DRB1*0401. J. Clin. Invest. 98, 2597–2603 (1996).
Ito, K. et al. HLA–DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J. Exp. Med. 183, 2635–2644 (1996).
Neeno, T. et al. HLA-DQ8 transgenic mice lacking endogenous class II molecules respond to house dust allergens. J. Immunol. 156, 3191–3195 (1997).
Dillon, S. R. et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nature Immunol. 5, 752–760 (2004).
Blumel, J., Schimpl, A., Ulrich, P., Ahr, H. J. & Vohr, H. Primary immune response in skin and skin-associated lymphoid tissue of interleukin-4 transgenic mice. Eur. Cytokine Netw. 10, 515–524 (1999).
Fallon, P. G., Emson, C. L., Smith, P. & McKenzie, A. N. IL-13 overexpression predisposes to anaphylaxis following antigen sensitization. J. Immunol. 166, 2712–2716 (2001).
Robles, M. S., Leonardo, E., Criado, L. M., Izquierdo, M. & Martinez, A. C. Exacerbated inflammatory responses in transgenic mice expressing an inhibitor of apoptosis protein (OpIAP). Cell Death Differ. 10, 1226–1233 (2003).
Mizumoto, N. et al. Enhanced contact hypersensitivity in human monocyte chemoattractant proptein-1 transgenic mouse. Immunobiology 204, 477–493 (2001).
Sato, T. et al. Consequences of OX40–OX40 ligand interactions in Langerhans cell function: enhance contact hypersensitivity responses in OX40L-transgenic mice. Eur. J. Immunol. 32, 3326–3335 (2002).
Seki, Y. et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nature Med. 9, 1047–1054 (2003).
Voice, J. K. et al. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J. Immunol. 170, 308–314 (2003).
Moser, R., Quesniaux, V. & Ryffle, B. Use of transgenic animals to investigate drug hypersensitivity. Toxicology 158, 75–83 (2001).
Bugelski, P. J. et al. Preclinical development of keliximab, a primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum. Exp. Toxicol. 19, 230–243 (2000).
Herzyk, D. J. et al. Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice. Infect. Immun. 69, 1032–1043 (2001).
Herzyk, D. J., Bugelski, P. J., Hart, T. K. & Wier, P. J. Practical aspects of including functional endpoints in developmental toxicity studies. Case study: immune function in HuCD4 transgenic mice exposed to anti-CD4 MAb in utero. Hum. Exp. Toxicol. 21, 507–512 (2002).
Josephy, P. D., Mannervik, B. & Ortiz de Montellano, P. Molecular Toxicology (Oxford Univ. Press, New York, Oxford, 1997).
Tanaka, E. Update: genetic polymorphisms of drug metabolizing enzymes in humans. J. Clin. Pharm. Ther. 24, 323–329 (1999).
Matzinger, P. Tolerance, danger and the extended family. Ann. Rev. Immunol. 12, 991–1045 (1994).
Shi, Y., Zheng, W. & Rock, K. L. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc. Natl Acad. Sci. USA 97, 14590–14595 (2000).
Curtsinger, J. M. et al. Inflammatory cytokines provide a third signal for activation of naïve CD4+ and CD8+ T cells. J. Immunol. 162, 3256–3262 (1999).
Pohl, L. R. Drug-induced allergic hepatitis. Sem. Liver Dis. 10, 305–315 (1990).
Naisbitt, D. J. Drug hypersensitivity reactions in skin: understanding mechanisms and development of diagnostic and predictive tests. Toxicology 194, 179–196 (2004).
Chenoweth, C. E., Judd, W. J., Steiner, E. A. & Kauffman, C. A. Cefotetan-induced hemolytic anemia. Clin. Infect. Dis. 15, 863–865 (1992).
Kunkeler, L., Nieboer, C. & Bruynzeel, D. P. Type III and type IV hypersensitivity reactions due to mitomycin C. Contact Dermatitis 42, 74–76 (2000).
Schnyder, B. et al. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazole-induced skin reactions. Clin. Exp. Allergy 28, 11412–11417 (1998).
Kalish, R. S., LaPorte, A., Wood, J. A. & Johnson, K. L. Sulfonamide-reactive lymphocytes detected at very low frequency in the peripheral blood of patients with drug-induced eruptions. J. Allergy Clin. Immunol. 94, 465–472 (1994).
Wälti, M., Neftel, K., Cohen, M., de Weck, A. L. & Perisic, M. Nachweis von arzneimittel-spezifischen IgE und IgG-antiköpern RIA: klinische bedeutung am bielspiel nomifensin (Alival). Schweizerische Medizinizche Wochenschrift 113, 1865–1867 (1983).
Clarke, J. B. et al. Detection of antidrug IgG antibodies in patients with adverse drug reactions. Int. Arch Allergy Appl. Immunol. 95, 369–375 (1991).
Kelkar, P. S. & Li, J. T. -C. Cephalosporin allergy. N. Engl. J. Med. 345, 804–809 (2001).
Verrotti, A., Trotta, D., Salladini, C. & Chiarelli, F. Anticonvulsant hypersensitivity syndrome in children. CNS Drugs 16, 197–205 (2002).
Levine, B. & Redmond, A. Immunochemical mechanisms of penicillin induced immune haemolytic anaemia in man. Int. Arch Allergy Appl. Immunol. 21, 594–606 (1967).
Ray, D. C. & Drummond, G. B. Halothane hepatitis. Br. J. Anaesth. 67, 84–99 (1991).
Acknowledgements
This work was supported by Centocor Inc.
Author information
Authors and Affiliations
Related links
Related links
DATABASES
Entrez Gene
OMIM
FURTHER INFORMATION
The Louisiana State University Library Toxicology Internet Resources page
Glossary
- XENOBIOTIC
-
This term is used to differentiate chemical drugs from protein therapeutics. They are generally polycyclic hydrocarbons that contain one or more nitrogen atoms, either as part of one or more of their rings, or as part of their side chains.
- HAPTEN
-
The designation given to a small molecule that is by itself non-immunogenic, but, when covalently linked to a protein, is able to elicit an immune response.
- DRUG-METABOLIZING ENZYMES
-
Enzymes that use xenobiotics as substrates for a wide range of chemical reactions. These include oxidations, reductions and conjugations. Metabolic enzymes can both activate and detoxify xenobiotic drugs. In immune-mediated adverse drug effects, metabolic enzymes often allow xenobiotics to act as haptens.
- CYTOCHROME P450
-
An important family of monooxygenases that mediate the metabolism of xenobiotics
- MAJOR HISTOCOMPATIBILITY COMPLEX
-
(MHC). Originally named because they function as transplantation antigens, MHC molecules have a crucial role in antigen presentation, and serve as accessory binding proteins for both T-helper and T-killer cells.
- ANTIGEN
-
An entity that is able to bind antibodies or T-cell receptors and elicit an immune response. Not all antigens are immunogens (that is, they are not all able to perform the de novo activation of an immune response). In immune-mediated adverse drug effects, although the parent xenobiotic drugs can function as antigens, they must often be covalently bound to proteins (see haptens) for full antigenicity.
- CLONES
-
Exact copies of a single progenitor cell. The clonal expansion of T and B cells is crucial in mounting an immune response.
- CYTOKINE
-
Protein hormones that act on cells of the immune system. Interleukins are cytokines that are released by leukocyte cells, which serve as crucial factors that drive and direct immune responses.
- ANTIBODY SUBCLASS
-
Antibodies are produced as five subclasses: immunoglobulin M (IgM), IgG, IgE, IgD and IgA. These differ in their heavy chains and, therefore, in their Fc receptor interactions. In immune-mediated adverse drug effects, IgE is important in mediating allergic (type I) reactions, whereas IgM and IgG are important effectors in type II, III and IV reactions.
- CHEMOKINES
-
Non-peptide and small peptide molecules that are able to mediate the migration of inflammatory cells from blood vessels to the site of inflammation.
- T-HELPER CELL
-
The subclass of T lymphocytes that mediates the expansion and direction of immune responses.
- KILLER CELL
-
The subclass of T lymphocytes that mediate damage to cells or tissues. Killer cells are important effector cells in delayed-type hypersensitivity reactions. They also act as suppressor cells to downregulate immune responses.
Rights and permissions
About this article
Cite this article
Bugelski, P. Genetic aspects of immune-mediated adverse drug effects. Nat Rev Drug Discov 4, 59–69 (2005). https://doi.org/10.1038/nrd1605
Issue Date:
DOI: https://doi.org/10.1038/nrd1605
This article is cited by
-
Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
BMC Medical Genetics (2011)
-
Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity
Clinical Pharmacology & Therapeutics (2010)